Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a placebo-controlled trial of CIT-013 in hidradenitis suppurativa
2025-521684-12-00Phase 2Authorised
- Sponsor
- Citryll
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of CIT013 in hidradenitis suppurativa (HS) (3 arms), sponsored by Citryll. Primary endpoint: HiSCR75 response at Day 85. Planned start Jan 2026; status: authorised.
02
Drugs
CIT013
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-521684-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521684-12-00.